Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mg
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Infection
Conditions
HIV Infection, HIV
Trial Timeline
Mar 1, 2026 → Jan 1, 2028
NCT ID
NCT07209267About Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mg
Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mg is a phase 2 stage product being developed by Eli Lilly for HIV Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07209267. Target conditions include HIV Infection, HIV.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07209267 | Phase 2 | Recruiting |
Competing Products
20 competing products in HIV Infection